Univ.-Prof. Dr. med. M. Subklewe
Senior physician, Head of Immunotherapy in Hematology, LMU – University Hospital Munich
Topic: Evolution in Cancer Therapy: BiTE, CART and Beyond
Bispecific antibodies and CART cells have revolutionized the therapy of various cancers. Numerous T cell recruiting antibodies (n=4) and CART cell products (n=6) are now approved for various lymphoid neoplasms. Current research activities are aimed at improving therapeutic outcomes with a better side effect profile. A review of the last 3 years.
Dr. Garwin Pichler
CEPO Preomics GmbH
Topic: PreOmics – Setting the Standard for Protein Analysis
PreOmics was founded in 2016 by Dr. Garwin Pichler and Dr. Nils A. Kulak as a spin-out company from the laboratory of leading proteomics researcher Prof. Matthias Mann at the MPI of Biochemistry. PreOmics develops and commercializes innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis by mass spectrometry globally to leading pharmaceutical companies and academic institutions.
Welcome / Moderation
Dr. Peter Hanns Zobel
Managing Director of the IZB
News from the IZB